Retour sur lavenir.net
   UCB 210.300 € (-0,14 %)     NYXOAH 1.426 € (-4,68 %)     WDP 21.260 € (-1,76 %)     KINEPOLIS GROUP 48.150 € (-0,82 %)     ELIA GROUP 120.400 € (+1,09 %)     CENERGY 23.620 € (+2,87 %)     ASCENCIO 53.300 € (0,00 %)     XIOR 26.100 € (-3,51 %)     DEME GROUP 181.400 € (-0,87 %)     AGEAS 75.750 € (-0,85 %)     JENSEN-GROUP 75.600 € (0,00 %)     AGFA-GEVAERT 0.411 € (-2,38 %)     KBC ANCORA 95.700 € (+0,53 %)     ENERGYVISION 16.920 € (-1,63 %)     EVS 28.900 € (-1,03 %)     TUBIZE-FIN 177.900 € (-0,45 %)     AEDIFICA 67.150 € (-0,44 %)     CMB.TECH 16.800 € (+0,12 %)     DECEUNINCK 2.385 € (0,00 %)     RECTICEL 12.480 € (-3,26 %)     VAN DE VELDE 30.000 € (0,00 %)     BELYSSE GROUP 0.422 € (-7,05 %)     HOME INVEST BE. 18.680 € (-1,89 %)     TITAN S.A. 53.300 € (-1,57 %)     COLRUYT 39.380 € (-0,35 %)     SOFINA 255.600 € (+1,43 %)     D'IETEREN GROUP 176.400 € (-2,22 %)     SHURGARD 22.350 € (-2,61 %)     INCLUSIO SA/NV 16.900 € (+0,60 %)     CIE BOIS SAUVAGE 308.000 € (0,00 %)     SYENSQO 80.350 € (-1,23 %)     FAGRON 21.700 € (+0,23 %)     BEKAERT 38.850 € (-1,40 %)     GIMV 45.600 € (+1,79 %)     RETAIL ESTATES 65.400 € (-1,65 %)     ATENOR 1.150 € (-4,17 %)     AB INBEV 68.020 € (-1,48 %)     ARGENX SE 869.400 € (-2,71 %)     MONTEA 64.700 € (-0,92 %)     SIPEF 105.200 € (+0,96 %)     AZELIS GROUP 12.000 € (-2,52 %)     TINC 11.180 € (-0,53 %)     UMICORE 22.620 € (-1,31 %)     FLUXYS BELGIUM D 22.300 € (-2,19 %)     BARCO 7.995 € (-0,62 %)     PROXIMUS 6.260 € (-1,34 %)     KBC 134.400 € (+0,90 %)     CAMPINE 182.000 € (-1,09 %)     BPOST 1.280 € (-1,08 %)     CARE PROPERTY INV. 12.440 € (-1,43 %)     HYLORIS 4.400 € (-2,00 %)     IMMOBEL 21.000 € (+3,45 %)     NEXTENSA 46.200 € (-1,35 %)     VASTNED 28.500 € (-1,04 %)     MELEXIS 67.850 € (+3,04 %)     SOLVAC NOM(RETAIL) 85.000 € (+0,59 %)     ONTEX GROUP 2.340 € (-4,49 %)     ONWARD MEDICAL 2.500 € (-0,20 %)     WERELDHAVE BELGIUM 51.000 € (+0,79 %)     ORANGE BELGIUM 22.100 € (0,00 %)  
   LISI 61.000 € (+0,33 %)     VALLOUREC 18.865 € (+1,21 %)     MAAT PHARMA 2.880 € (-2,04 %)     TOTALENERGIES 77.300 € (+1,58 %)     WORLDLINE 14.212 € (-2,31 %)     GTT 220.000 € (+1,76 %)     EUROPLASMA 0.001 € (+33,33 %)     ASR NEDERLAND 73.960 € (-0,62 %)     SHOWROOMPRIVE 1.050 € (+9,38 %)     SHELL PLC 40.560 € (+1,13 %)     ARKEMA 59.050 € (-0,42 %)     SARTORIUS STED BIO 186.500 € (-2,00 %)     MERSEN 38.700 € (+2,54 %)     ALSTOM 16.300 € (-1,21 %)     SAINT GOBAIN 74.620 € (-1,53 %)     VINCI 113.600 € (-0,31 %)     EXOSENS 57.450 € (+4,08 %)     MICHELIN 34.470 € (-1,96 %)     BENETEAU 5.690 € (-1,39 %)     SOLUTIONS 30 SE 0.538 € (-0,55 %)     CROSSJECT 1.400 € (+4,48 %)     ADP 108.200 € (-1,10 %)     RIBER 9.480 € (+10,75 %)     ARCADIS 43.980 € (-0,99 %)     ROBERTET 791.000 € (-0,75 %)     BNP PARIBAS ACT.A 104.540 € (0,00 %)     CARREFOUR 16.270 € (-0,82 %)     TETRAGON FIN GRP 14.100 € (+0,71 %)     CRCAM BRIE PIC2CCI 37.200 € (+0,54 %)     AMG 32.660 € (+3,55 %)     KERING 241.400 € (-1,55 %)     CASINO GUICHARD 0.184 € (-0,16 %)     ESSILORLUXOTTICA 148.550 € (-0,83 %)     ACCOR 46.650 € (-0,53 %)     IMERYS 24.660 € (+1,40 %)     PHARMING GROUP 0.982 € (+1,34 %)     ATOS GROUP 26.220 € (-2,24 %)     HAFFNER ENERGY 0.668 € (+12,84 %)     SCHNEIDER ELECTRIC 295.500 € (+2,60 %)     VICAT 65.700 € (+0,31 %)     AKZO NOBEL 60.160 € (-0,95 %)     AHOLD DEL 31.100 € (-1,77 %)     PARROT 9.250 € (-1,28 %)     SPIE 43.780 € (-0,05 %)     ABN AMRO BANK N.V. 43.420 € (+0,67 %)     WINFARM 3.900 € (0,00 %)     WAVESTONE 31.800 € (-1,24 %)     SOITEC 143.350 € (+11,73 %)     ARCELORMITTAL SA 67.540 € (+0,45 %)     SOCIETE GENERALE 75.070 € (+1,20 %)     ALTAREA 88.700 € (-2,53 %)     KAUFMAN ET BROAD 22.550 € (-2,38 %)     ARGAN 72.400 € (-1,76 %)     SANOFI 75.690 € (-0,75 %)     CREDIT AGRICOLE 18.865 € (+0,32 %)     CTP 13.700 € (-1,30 %)     AMOEBA 0.629 € (+0,64 %)     OMER-DECUGIS & CIE 8.400 € (0,00 %)     AXA 44.160 € (-1,08 %)     ASM INTERNATIONAL 862.200 € (+4,48 %)  
News Réglementées
07/09/2026 13:00

Clearway Capital rejects GZO's proposed composition agreement

Lemongrass Communications AG / Key word(s): Legal Matter
Clearway Capital rejects GZO's proposed composition agreement

07.09.2026 / 13:00 CET/CEST


Media Release

Clearway Capital urges creditors to reject GZO's proposed composition agreement

Zurich, 7 September 2026 Clearway Capital Partners ICAV (“Clearway”), a creditor of GZO AG Spital Wetzikon (“GZO”) leading the GZO Creditor Group, announces that it will vote against the composition agreement (Nachlassvertrag) to be put to creditors at the assembly expected in the second half of October 2026, and urges all creditors to do the same.

Creditors are being asked to approve the inferior of two offers. GZO’s plan, built around thurmed AG as strategic investor, delivers just CHF 70.1 million in cash, equal to 29.0% of claims. The headline recovery of 39.3–47.5% materially overstates the economic value being offered, as it relies on deferred and highly uncertain components: 10.3% is stretched over ten years without interest or security; a further 8.2% depends entirely on the outcome of GZO’s dispute with Steiner; and the additional EBITDA-linked payment cannot be quantified as it requires GZO to achieve an 8% operating margin, far above the 5.1% delivered in 2025. Clearway therefore assigns no value to the contingent components and only minimal present value to the deferred payment.

Creditors were denied the opportunity to compare the proposal against a materially better alternative, which was rejected by the company. On 29 July 2026, Infracore SA made a binding, fully financed offer of CHF 55 million in cash for GZO's real estate, payable upon confirmation of the composition agreement. Together with the CHF 96.5 million of cash and securities in GZO's audited 2025 accounts, Clearway estimates that this offer could have supported an immediate cash recovery of up to 60% - roughly double what creditors are now being asked to accept.

GZO terminated the Infracore offer on the basis of an assessment by its financial adviser PwC, which has not been shared with creditors. It is not the first time creditors have been asked to accept an advisor's conclusion in place of the underlying analysis. The bankruptcy comparison used to sell the current plan rests on a liquidation status that values GZO's entire fixed-asset base at CHF 12.0 million, and the hospital parcel itself at zero. A binding offer has now put a market price on that same real estate: CHF 55 million, more than four times the figure creditors were given.

Importantly for all creditors, this vote will not be decided by headcount alone. Under Article 305 SchKG, creditors holding just over one-third of total claims can block the agreement regardless of the number of heads voting in favor. At the September 2025 assembly, creditors representing some CHF 165 million of claims, approximately two-thirds of the total, were already aligned with Clearway's position. It is therefore of the utmost importance that as many creditors as possible participate in the assembly and cast their vote. Clearway is confident that the agreement will not pass in its current form and urges all creditors to participate, either in person or via proxy.

“Creditors are being asked to write off 70% of their claims to recapitalize a hospital in which they will receive no ownership, no security and no interest on the amounts still owed to them. At the same time, GZO rejected a substantially superior offer without giving creditors the opportunity to consider it,” said Gianluca Ferrari, founder of Clearway Capital.

“This is not a plan based on what GZO can afford to pay. It is a plan based on how little GZO believes creditors can be persuaded to accept,” he added.

Clearway will provide creditors with further updates ahead of the assembly, and practical assistance to any creditor wishing to vote against the agreement. Clearway is also evaluating all options at its disposal to protect creditor interests, including with regard to the decisions that have brought creditors to this point.

Creditors are invited to contact Clearway directly with questions regarding the exercise of their vote.

 

Contact for Media:
Lemongrass Communications AG

susanne.muehlemann@lemongrass.agency
+41 79 223 70 81

Contact for Investors:

contact@gzo-bondholder.ch

About Clearway Capital:

Clearway Capital Partners is an alternative investment fund that invests in special situations in Western European markets where seeks to unlock value through responsible ownership. With a focus on protecting investor rights and ensuring fair treatment of stakeholders, Clearway Capital actively advocates for transparent and equitable corporate practices.

 


Additional features:

File: Clearway_GZO_MM_07_09_26_E


End of Media Release
View original content: EQS News


2394934  07.09.2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière